The Ras-related gene ERAS is involved in human and murine breast cancer
Entidad
UAM. Departamento de Bioquímica; Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM); Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)Editor
Nature Research (part of Springer Nature)Fecha de edición
2018-08-29Cita
10.1038/s41598-018-31326-4
Scientific Reports 8 (2018): 13038
ISSN
2045-2322DOI
10.1038/s41598-018-31326-4Financiado por
This research was supported partially by funds from Fondo Europeo de Desarrollo Regional (FEDER) and by grants from the Spanish Government PI16/00161, PI16/00134, PIE15/00076, PI17/00578, CB/16/00228, CB16/12/00295 and RD12/0036/0009 from Instituto de Salud Carlos III (Ministerio de Economía y Competitividad) and SAF-2015-66015-R from the Ministerio de Economía y Competitividad. Biobanco 1 + 12 is supported by Instituto de Salud Carlos IIIProyecto
Gobierno de España. PI16/00161; Gobierno de España. PI16/00134; Gobierno de España. PIE15/00076; Gobierno de España. PI17/00578; Gobierno de España. CB/16/00228; Gobierno de España. CB16/12/00295; Gobierno de España. RD12/0036/0009; Gobierno de España. SAF-2015-66015-RVersión del editor
https://doi.org/10.1038/s41598-018-31326-4Materias
Ras gene; Human tumors; Breast cancer; Metastasis; New specific treatments; MedicinaDerechos
© 2018, The Author(s)Resumen
Although Ras genes are frequently mutated in human tumors, these mutations are uncommon in breast cancer. However, many breast tumors show evidences of Ras pathway activation. In this manuscript, we have analyzed and characterized mouse mammary tumors generated by random Sleeping Beauty transposon mutagenesis and identify ERAS -a member of the RAS family silenced in adult tissues- as a new gene involved in progression and malignancy of breast cancer. Forced expression of ERAS in human non-transformed mammary gland cells induces a process of epithelial-to-mesenchymal transition and an increase in stem cells markers; these changes are mediated by miR-200c downregulation. ERAS expression in human tumorigenic mammary cells leads to the generation of larger and less differentiated tumors in xenotransplant experiments. Immunohistochemical, RT-qPCR and bioinformatics analysis of human samples show that ERAS is aberrantly expressed in 8–10% of breast tumors and this expression is associated with distant metastasis and reduced metastasis-free survival. In summary, our results reveal that inappropriate activation of ERAS may be important in the development of a subset of breast tumors. These findings open the possibility of new specific treatments for this subset of ERAS-expressing tumors.
Lista de ficheros
Google Scholar:Suárez-Cabrera, Cristian
-
Peña, Bárbara de la
-
González, Laura L.
-
Page, Angustias
-
Martínez-Fernández, Mónica
-
Casanova, M. Llanos
-
Paramio, Jesús M.
-
Rojo-Sebastián, Alejandro
-
Moreno Bueno, Gema
-
Maroto, Alicia
-
Ramírez, Ángel
-
Navarro, Manuel
Lista de colecciones del ítem
Registros relacionados
Mostrando ítems relacionados por título, autor, creador y materia.
-
Corrigendum to “Prostaglandin F2a-induced prostate transmembrane protein, androgen induced 1 mediates ovarian cancer progression increasing epithelial plasticity” [Neoplasia 21 (2019) 1073–1084]
Jiménez-Segovia, Alba; Mota, Alba; Rojo-Sebastián, Alejandro; Barrocal, Beatriz; Rynne-Vidal, Ángela; García-Bermejo, María Laura; Gómez-Bris, Raquel; Hawinkels, Lukas J A C; Sandoval, Pilar; García-Escudero, Ramón; López-Cabrera, Manuel; Moreno Bueno, Gema; Fresno Escudero, Manuel
; Stamatakis, Konstantinos
2020-05 -
Prostaglandin F 2α-induced prostate transmembrane protein, androgen induced 1 mediates ovarian cancer progression increasing epithelial plasticity
Jiménez-Segovia, Alba; Mota, Alba; Rojo-Sebastián, Alejandro; Barrocal, Beatriz; Rynne-Vidal, Ángela; García-Bermejo, Mara-Laura; Gómez-Bris, Raquel; Hawinkels, Lukas J.A.C.; Sandoval, Pilar; García-Escudero, Ramón; López-Cabrera, Manuel; Moreno Bueno, Gema; Fresno Escudero, Manuel
; Stamatakis, Konstantinos; Centro de Biología Molecular Severo Ochoa (CBMSO); Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM); Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP)
2019